A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

N/ACompletedNCT03769558

Bristol-Myers Squibb264 enrolled

Overview

This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept

Study Type

OBSERVATIONAL

Enrollment

264

Conditions

Juvenile Idiopathic Arthritis

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 12 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Two diagnoses of JIA (ICD-9 code 714.3x) within 90 days * Age less than 18 years at the time of second of the two diagnoses * Index date is the date of initiating treatment with abatacept Exclusion Criteria: * Greater than or equal to 18 years of age

Locations (1)

Local Institution

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Incidence of infections

Time frame: 110 months

Secondary Outcomes

Incidence of malignancies

Time frame: 110 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.